

Sofosbuvir–velpatasvir–voxilapre for treating chronic hepatitis C

Information for the public

Published: 21 February 2018

www.nice.org.uk

Sofosbuvir–velpatasvir–voxilaprevir (Vosevi) is available on the NHS. It is a possible treatment for adults with hepatitis C (with or without compensated liver cirrhosis). See table 1.

Table 1 Sofosbuvir-velpatasvir-voxilaprevir for treating chronic hepatitis C (with or without compensated liver cirrhosis)

Hepatitis C genotype	Treatment history	Recommendation
1 to 6	Previous direct-acting antivirals	Recommended for 12 weeks
3	No direct-acting antivirals	Recommended for 8 weeks

If you are not eligible for sofosbuvir–velpatasvir–voxilaprevir, but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

[NHS Choices](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Hepatitis C Trust](#), 020 7089 6221
- [HIV-i-Base](#), 0208 616 2210
- [Terrence Higgins Trust](#), 0808 802 1221
- [British Liver Trust](#), 0800 652 7330
- [Liver4Life](#), 0800 074 3494

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2843-9